iLivTouch® Clinical research
2025-05-19
Prevalence of liver fibrosis as defined by non-invasive markers in non-HBV Chinese general population with Normal ALT: a large population study
We investigated the prevalence and risk factors related to liver fibrosis in a large cohort of Chinese general population with normal alanine aminotransferase (ALT ≤ 40U/L)
2025-05-19
Effect of a High Protein, Low Glycemic Index Dietary Intervention on Metabolic Dysfunction Associated Fatty Liver Disease: A Randomized Controlled Trial (IF=5.0)
To evaluate whether a high protein and low glycemic index (HPLG) dietary intervention would result in improvement of controlled attenuation parameter (CAP) and related metabolic markers in MAFLD.
2025-05-19
A cross-sectional study of alcohol consumption and alcoholic liver disease in Beijing: based on 74,998 community residents (IF=4.5)
The alcohol consumption pattern, alcoholic liver disease (ALD) prevalence and related risk factors among alcohol drinkers in Beijing haven't been fully elucidated. Hence, a cross-sectional study was conducted to investigate potential link among these factors.
2025-05-19
Metabolic dysfunction-associated fatty liver disease (MAFLD) and advanced liver fibrosis among hemodialysis patients in a multiethnic urban population in Malaysia (IF=1.6)
To study the prevalence of MAFLD and advanced liver fibrosis and the associated factors among hemodialysis patients in a multiracial urban population in Malaysia.
2025-05-19
Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China (IF=29.4)
To estimate the prevalence of liver steatosis and fibrosis in the general population and populations with potential risk factors in China, so as to inform policies for the screening and management of fatty liver disease and liver fibrosis in general and high-risk populations.
